Alligator Bioscience Q2 FY26 operating loss widens to SEK 36.2 million

Reuters2026/08/26 06:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alligator Bioscience posted a Q2 operating loss of SEK 36.2 million, widening from SEK 22.3 million a year earlier.
Net loss widened to SEK 37.8 million from SEK 1.7 million; cash and cash equivalents fell to SEK 16.6 million from SEK 33.9 million.
Announced a rights issue of units of about SEK 125.6 million, covered by subscription and guarantee commitments of about 47%.
Discontinued independent development of mitazalimab, seeking to out-license or divest it while refocusing on royalty potential from out-licensed HLX22.
Henlius reported first patients dosed across all regions in the global Phase 3 HLX22 study; follow-up beyond 39 months showed continued extended progression-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alligator Bioscience Q2 FY26 operating loss widens to SEK 36.2 million

You may also like

Crypto prices